Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

The FDA's Tala Fakhouri discusses the agency's approach to the regulation of AI in clinical trials in a new interview.

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...

The only available treatment for HDFN can itself be fatal, but a clinical trial led by an Austin researcher offers new hope ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...